Department of Oncology, McMaster University, Hamilton, ON L8S 4L8, Canada.
Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), Toronto, ON M5G 2L7, Canada.
Curr Oncol. 2021 Mar 1;28(2):1114-1124. doi: 10.3390/curroncol28020107.
To provide recommendations on systemic therapy options in consolidation or maintenance therapy for women with newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma including all histological types.
Consistent with the Program in Evidence-based Program's standardized approach, MEDLINE, EMBASE, PubMed, Cochrane Library, and PROSPERO (the international prospective register of systematic reviews) databases, and four relevant conferences were systematically searched. The Working Group drafted recommendations and revised them based on the comments from internal and external reviewers.
We have one recommendation for consolidation therapy and eight recommendations for maintenance therapy. Overall, consolidation therapy with chemotherapy should not be recommended in the target population. For maintenance therapy, we recommended olaparib (Recommendation), niraparib (Weak Recommendation), veliparib (Weak Recommendation), and bevacizumab (Weak Recommendation) for certain patients with newly diagnosed stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, respectively. We do not recommend some agents as maintenance therapy in four recommendations. We are unable to specify the patient population by histological types for different maintenance therapy recommendations. When new evidence that can impact the recommendations is available, the recommendations will be updated as soon as possible.
为新诊断为 II 期、III 期或 IV 期上皮性卵巢、输卵管或原发性腹膜癌的女性（包括所有组织学类型）提供巩固或维持治疗的系统治疗选择建议。
与循证方案计划的标准化方法一致，对 MEDLINE、EMBASE、PubMed、Cochrane 图书馆和 PROSPERO（国际系统评价前瞻性注册库）数据库以及四个相关会议进行了系统搜索。工作组起草了建议，并根据内部和外部审查员的意见对其进行了修订。
我们有一项关于巩固治疗的建议和八项关于维持治疗的建议。总体而言，在目标人群中不建议使用化疗进行巩固治疗。对于维持治疗，我们建议对于新诊断的 III 期-IV 期上皮性卵巢、输卵管或原发性腹膜癌的某些患者使用奥拉帕利（推荐）、尼拉帕利（弱推荐）、维利帕利（弱推荐）和贝伐珠单抗（弱推荐）。在四项建议中，我们不建议使用某些药物作为维持治疗。我们无法根据不同的维持治疗建议为不同的组织学类型的患者指定人群。当有新证据可能影响建议时，将尽快更新建议。
